The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Eric M. Parker et al.|Science Translational Medicine|2016Cited by 416
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.Elena Garralda, Gerald S. Falchook, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2021Cited by 46